Clinical Trial Update: A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 9MW3011 in patients with polycythemia vera; recruitme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• 9MW3011

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Polycythemia Vera | Phase 1 | Status: RECRUITING